Aktiespararna: Aktiedagen Stockholm
VD Michael-Robin Witt presenterar Gabather på Aktiespararnas Aktiedagen i Stockholm 7 september 2021
Läs merCEO ANFÖRANDE PÅ ÅRSSTÄMMAN 2021
BioStock Life Science Spring Summit 2021
CEO Michael-Robin Witt presents Gabather at the spring edition of BioStock Life Science Summit 2021.
Läs merBiostock: Covid unmasks need for better mental health medication
As researchers continue working around the clock to put together the puzzle pieces needed for better understanding Covid-19 pathology, the disease has further exposed a serious lack of treatments for mental health conditions. In Sweden, biotech Gabather is developing new treatments for CNS diseases, including psychiatric disorders that appear in many
Läs merBioStock Studio: Gabather gives clinical trial update
BioStock Studio: Gabather gives clinical trial update – BioStock
Läs merFinWire: Aktieportföljen Live 10 Mars
Biostock: Q4 report points to progress in the clinic for Gabather
Last week, Gabather published its 2020 year-end report, which shows that the company is ramping up its clinical development with GT-002. Going forward the company will focus on studying the effects of its top candidate on brain activity, which will be a key step in determining dosage of GT-002 to
Läs merQA med VD Michael Robin Witt
Kliniska studier Ni väntade er att den slutliga studierapporten för fas 1b skulle bli tillgänglig i slutet av förra året. Årsskiftet är passerat utan vare sig studierapport eller förklaring till varför den är sen. Varför saknas besked ang. detta, får ni inte kommunicera saken eller har ni inte ansett det
Läs merBiostock: Focus on CNS Diseases
Diseases of the central nervous system (CNS) and mental health issues represent a major burden on society, and there is considerable room for improvements of the current therapeutic alternatives. Swedish pharma company Gabather is working to alleviate this burden by developing therapies targeting the GABAA receptor, which is involved in a
Läs mer